1PARK T S, HOFFMAN H U, HENDRICK E B, et al. Medullo- hiastoma: clinical presentation and management. Experience at the hospital for sick children, toronto, 1950 - 1980[ J]. J Neurosurg, 1983, 58(4): 543 -552.
2AGUILERA D, MAZEWSKI C, FANGUSARO J, et al. Response to bevacizumab, irinotecan, and temozolomide in children with re-lapsed medulloblastoma: a multi - institutional experience [ J ]. Childs Nerv Syst, 2013, 29(4) : 589 -596.
3GRILL J, REOERGER B, GESNER L, et al. Phase 11 study of irinotecan in combination with temozolomide (TEMIRI) in chil- dren with recurrent or refractory medulloblastoma: a joint ITCC and SLOPE brain tumor study[J]. Neuro Onto1, 2013, 15(9) : 1236 - 1243.
4PACKER R J, SUTI'ON L N, GOLDWEIN J W, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma[J]. J Nerurosurg, 1991,74(3) : 433 -440.
5KOMBOGIORGAS D, SGOUROS S, WALSH A R, et al. Out- come of children with posterior fossa medulloblastoma: a single in- stitution experience over the decade 1194 -2003 [ J ]. Childs Nerv Syst, 2007, 23(4): 399-405.
